Sorafenib: New reference standard for systemic treatment of advanced hepatocellular carcinoma

Community Oncology

Volumn 4, Issue 9, 2007, Pages 529-530

  Lau, Yiu Keung ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; SORAFENIB;

ADVANCED CANCER; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DRUG TOLERABILITY; HAZARD RATIO; HUMAN; LIVER CELL CARCINOMA; SHORT SURVEY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 35348976055     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70028-6     Document Type: Short Survey

References (5)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society, 2007. Available at: http://www.cancer.org/downloads/ STT/CAFF2007PWSecured.pdf. Accessed July 24, 2007.
2. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 1988;62:479-483.
3. Yang TS, Chang WC, Lin YC, Chen JS, Liau CT, Yeh KY. A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol 2003;22:1351.
4. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007;25(18S):LBA1.
5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers v.2.2007. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/hepatobiliary.pdf. Accessed August 16, 2007.